Anti-VEGF Therapeutics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)

Anti-VEGF Therapeutics Market Growth Drivers & Opportunities

Growing Incidence of Eye Diseases Drives Market

• The most-significant driver for the anti-vascular endothelial growth factor market is the rising incidence of eye disease.
• These drugs are most commonly prescribed for AMD, diabetic retinopathy, macular edema, and retinal vein occlusion, all of which are rising incidence.
•  According to reports, almost 200 million people around the world have age-related macular degeneration.
• Additionally, 1 in 4 people in the U.S. above the age of 40 suffer from diabetic retinopathy.
• Similarly, macular edema is diagnosed in around 5.5% of the people with diabetes.
• Anti-VEGF drugs are often used to slow down the formation of excess blood vessels in the eyes that cause these conditions.

Patent Expirations Offer Business Opportunity to Biosimilar Firms

• Patents for Ranibizumab and Aflibercept in the U.S. expired in 2020 and 2022, respectively, while in Europe, they will expire in 2025.
• However, due to the economic effectiveness and availability of diverse choices of biosimilars, the USFDA and the European Medicines Agency (EMA) are predicted to approve a slew of biosimilars for clinical use in the near future, thus opening doors for biosimilar manufacturing companies and CDMOs.
• For instance, Xbrane developed Xlucane, in February 2022, a Lucentis biosimilar candidate under registration partnered with STADA and Bausch + Lomb, yet to be approved by the FDA.

Anti-VEGF Therapeutics Market Analysis

Product Insights

Eylea holds the largest market share, of 60%, in 2024, and it is also expected to maintain its position during the forecast period. This is attributed to the ongoing research and development activities in this area. For instance, Regeneron has been conducting a phase-2 proof-of-concept study comparing the 8 mg dose against the established 2 mg dose to investigate if a higher dose can benefit wet AMD patients.

Beovu is expected to gain momentum at the highest CAGR, of approximately 4%, in the coming years. Moreover, it received approval from EC for the management of visual impairment, owing to diabetic macular edema (DME), in March 2022, and thus, it can be used in all 27 EU member states as well as Iceland, Norway, and Liechtenstein. Therefore, the approvals from several organizations drive the market growth in this category.

The following products have been analyzed:

• Eylea (Largest Category)
• Lucentis
• Beovu (Fastest-Growing Category)
• Others

Disease Insights

AMD dominates the market with 55% share in 2024, owing to the increasing cases of AMD. For instance, around 2 million persons aged 50 years and more were blind as a result of AMD, and 6.22 million people had moderate-to-severe vision impairment (MSVI), as of 2020, globally. However, the age-standardized prevalence of AMD blindness decreased by more than 20% during 2000–2020, due to the increasing awareness and rising adoption of anti-VEGF medications.

The diabetic retinopathy category is projected to witness the highest CAGR, of 4.1%, during 2025–2030, owing to the surging incidences of DR, globally. For instance, from around 100 million in 2020, the number of adults with this condition is expected to rise to more than 150 million by 2045.

The report offers insights into the below-mentioned diseases:

• Macular Edema
• Diabetic Retinopathy (Fastest-Growing Category)
• Retinal Vein Occlusion
• Age-Related Macular Degeneration (Largest Category)
• Others

Distribution Channel Insights

Hospital pharmacies will generate the highest revenue in this market, of USD 15 billion, by the end of 2024. Most patients with eye diseases treatable with anti-VEGF therapeutics visit full-fledged hospitals for diagnosis and treatment by trained professionals. They are prescribed drugs right there, which many prefer to purchase from onsite drugstores, to avoid the hassles of going somewhere else and for the trust they place in these stores.

The online pharmacies category will witness the highest CAGR, of 5%, during the forecast period. This is attributed to the increasing preference for online shopping on account of the many conveniences it offers to customers. Moreover, to stop alleged drug-seeking behavior, many governments have mandated that drugs only be dispensed through online platform on presentation of a signed doctor’s prescription. Additionally, with the integration of blockchains by online drugstores, the possibility of prescription fraud would reduce further.

The following distribution channels are covered:

• Hospital Pharmacies (Largest Category)
• Retail Pharmacies
• Online Pharmacies (Fastest-Growing Category)
• Others

Regional Analysis

• The North American anti-vascular endothelial growth factor therapeutics market will hold the largest revenue share, of around 60%, in 2024.
• This is attributed to the improvements in healthcare infrastructure, technological advancements, proactive government actions, rise in consumer awareness, and increase in disease prevalence.
• The U.S. leads the North American market, as most of the major companies are headquartered in the country, providing early and easy access to the latest innovations to patients.
• Moreover, private companies along with educational institutes and other organizations are involved in new product development and research and development activities.
• The Canadian market for anti-VEGF therapeutics is likely to witness significant growth during the forecast period owing to the approvals received by companies for anti-VEGF medications.
• For instance, Health Canada has approved Samsung Bioepis and Biogen's BYOOVIZ, a Lucentis biosimilar for the treatment of neovascular (wet) AMD and visual impairment due to DME, among others.
• The APAC market size is likely to propel at the highest CAGR, of approximately 4%, during 2025–2030. Licensing agreements between companies are one of the major factors driving the market growth.
• For instance, PanOptica and Zhaoke Ophthalmology Limited have entered into a licensing agreement to develop and commercialize PAN-90806, a topical eye drop for the treatment of neovascular eye diseases, including wet AMD and DR, in China, South Korea, and Southeast Asia.
• Japan holds the largest revenue share in the APAC market currently.
• This is because the country ranks number one, in terms of the geriatric population, with more than 25% of the total population being above 65 years of age, resulting in high incidences of AMD and DR, among other diseases.
• Thus, companies are introducing new treatments for such diseases.
• For instance, Chugai Pharmaceutical has launched Vabysmo Intravitreal Injection 120 g/mL (faricimab) as an anti-VEGF/anti-Ang-2 bispecific antibody for the treatment of AMD associated with subfoveal choroidal neovascularization and DME, after receiving approval from the Ministry of Health, Labor and Welfare (MHLW) of Japan.

The following regions and countries have been studied:

• North America (Largest Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Faster-Growing Country Market)
• Europe
  • Germany (Largest Country Market)
  • France
  • U.K.
  • Italy (Fastest-Growing Country Market)
  • Spain
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China
  • India (Fastest-Growing Country Market)
  • Japan (Largest Country Market)
  • Australia
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Argentina
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Fastest-Growing Country Market)
  • South Africa
  • U.A.E. (Largest Country Market)
  • Rest of MEA

Anti-VEGF Therapeutics Market Share

The anti-vascular endothelial growth factor market is consolidated because only a handful of pharmaceutical companies have received a regulatory approval for these drugs. Being an extensively regulated industry, pharmaceuticals present high entry barriers for new companies. R&D, production, clinical trials, and regulatory approval require high capital investments, which only established drug makers are able to make. Additionally, drug patents are heavily protected and can last for 20 years, prohibiting non-patent holders from making the drug. This is why as the more existing patents expire and biosimilar versions of these medicines emerge, the market might move toward fragmentation in future.

Anti-VEGF Therapeutics Market Company News

• In September 2024, F. Hoffmann-La Roche Ltd. inaugurated its new Pharma Research and Early Development (pRED) Center at its Basel, Switzerland, headquarters. The CHF 1.2-billion office houses 1,000 office and laboratory workplaces.
• In March 2024, Sandoz Inc. acquired Coherus Ophthalmology LLC from Coherus BioSciences Inc. for USD 170 million in cash.
• In February 2024, Bausch Health Companies Inc.’s majority-owned subsidiary Bausch + Lomb Corporation announced the receipt of the Category 1 CPT code 67516 from the American Medical Association, in collaboration with the American Society of Retina Specialists and American Academy of Ophthalmology (AAO), for XIPERE. This injectable suspension of triamcinolone acetonide is indicated for macular edema due to uveitis.
• In October 2023, Amgen Inc. acquired Horizon Therapeutics plc for USD 27.8 billion in cash, at a rate of USD 116.50 per share. The acquisition added Horizon’s TEPEZZA, KRYSTEXXA, and UPLIZNA to Amgen’s portfolio.